Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Zymeworks (ZYME – Research Report) yesterday and set a price target of $19.00. The company’s shares closed last Friday at $8.25.
According to TipRanks, Willey is a 5-star analyst with an average return of 13.5% and a 46.38% success rate. Willey covers the Healthcare sector, focusing on stocks such as Atreca, Exelixis, and Zymeworks.
Currently, the analyst consensus on Zymeworks is a Moderate Buy with an average price target of $12.88, implying a 56.12% upside from current levels. In a report released on May 18, Citi also maintained a Buy rating on the stock with a $18.00 price target.
See today’s best-performing stocks on TipRanks >>
ZYME market cap is currently $534.8M and has a P/E ratio of 3.19.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ZYME in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani, and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.
Read More on ZYME:
- 3 Best Stocks to Buy Now, 5/19/2023, According to Top Analysts
- Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer
- Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results
- Is ZYME a Buy, Before Earnings?
- Zymeworks Announces Participation in Upcoming Investor Conferences
